Vinbarbital

drug
On this page

Also known as NSC-117442Vinbarbital sodium free acid

Summary

Vinbarbital (CHEMBL503565) is an approved small molecule (ATC N05CA09).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N05CA09
  • Chemistry: 224.26 Da · C11H16N2O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL503565
NameVinbarbital
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID5284636
ATCN05CA09
Molecular formulaC11H16N2O3
Molecular weight224.26
InChIKeyRAFOHKSPUDGZPR-VOTSOKGWSA-N

SMILES: CC/C=C(\C)/C1(C(=O)NC(=O)NC1=O)CC

IUPAC name: 5-ethyl-5-[(E)-pent-2-en-2-yl]-1,3-diazinane-2,4,6-trione

Also known as: NSC-117442, Vinbarbital, Vinbarbital sodium free acid, VINBARBITAL

Patent coverage: 144 distinct patent families (563 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.